Convection-enhanced delivery for treatment of brain tumors

References

• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17(8), 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J. Clin. Oncol.24(8), 1273–1280 (2006).
   PubMed Web of Science ®Google Scholar
• Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology34(6), 463–469 (1992).
   PubMed Web of Science ®Google Scholar
• Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther.104(1), 29–45 (2004).
   PubMed Web of Science ®Google Scholar
• Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol.40(3), 648–677 (1969).
   PubMed Web of Science ®Google Scholar
• Hall WA, Rustamzadeh E, Asher AL. Convection-enhanced delivery in clinical trials. Neurosurg. Focus14(2), E2 (2003).
   PubMedGoogle Scholar
• Mahar Doan KM, Humphreys JE, Webster LO et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther.303(3), 1029–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Goldman DL, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood–brain barrier disruption: prolonged survival and preservation of cognitive function. J. Clin. Oncol.9(9), 1580–1590 (1991).
   PubMed Web of Science ®Google Scholar
• Rapoport SI. Osmotic opening of the blood–brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol.20(2), 217–230 (2000).
   PubMed Web of Science ®Google Scholar
• Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci. Lett.307(2), 77–80 (2001).
   PubMed Web of Science ®Google Scholar
• Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J. Pharmacol. Exp. Ther.195(1), 73–83 (1975).
   PubMed Web of Science ®Google Scholar
• Yan Q, Matheson C, Sun J, Radeke MJ, Feinstein SC, Miller JA. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp. Neurol.127(1), 23–36 (1994).
   PubMed Web of Science ®Google Scholar
• Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res.680(1–2), 196–206 (1995).
   PubMed Web of Science ®Google Scholar
• Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA91(6), 2076–2080 (1994).
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood–brain and blood–tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncology2(1), 45–59 (2000).
   PubMed Web of Science ®Google Scholar
• Guarnieri M, Carson BS, Khan A, Penno M, Jallo GI. Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues. J. Neurosci. Methods144(2), 147–152 (2005).
   PubMedGoogle Scholar
• Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg. Focus20(4), E12 (2006).
   PubMedGoogle Scholar
• Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J. Neurosurg.90(2), 315–320 (1999).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Brady ML, Petry NA et al. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery60(2 Suppl. 1), ONS89–ONS98; discussion ONS98–ONS99 (2007).
   PubMed Web of Science ®Google Scholar
• Vavra M, Ali MJ, Kang EW et al. Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro-oncology6(2), 104–112 (2004).
   PubMed Web of Science ®Google Scholar
• Saito R, Krauze MT, Noble CO et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncology8(3), 205–214 (2006).
   PubMed Web of Science ®Google Scholar
• MacKay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res.1035(2), 139–153 (2005).
   PubMed Web of Science ®Google Scholar
• Chen MY, Hoffer A, Morrison PF et al. Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J. Neurosurg.103(2), 311–319 (2005).
   PubMed Web of Science ®Google Scholar
• Bruce JN, Falavigna A, Johnson JP et al. Intracerebral clysis in a rat glioma model. Neurosurgery46(3), 683–691 (2000).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Archer GE, McLendon RE et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin. Cancer Res.6(10), 4148–4153 (2000).
   PubMed Web of Science ®Google Scholar
• Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery47(6), 1391–1398; discussion 1398–1399 (2000).
   PubMedGoogle Scholar
• Degen JW, Walbridge S, Vortmeyer AO, Oldfield EH, Lonser RR. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J. Neurosurg.99(5), 893–898 (2003).
   PubMed Web of Science ®Google Scholar
• Frewert S, Stockhammer F, Warschewske G et al. Intratumoral infusion of interleukin-1β and interferon-γ induces tumor invasion with macrophages and lymphocytes in a rat glioma model. Neurosci. Lett.364(3), 145–148 (2004).
   PubMedGoogle Scholar
• Hadaczek P, Kohutnicka M, Krauze MT et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther.17(3), 291–302 (2006).
   PubMed Web of Science ®Google Scholar
• Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol.65(1), 37–48 (2003).
   PubMed Web of Science ®Google Scholar
• Rainov NG, Soling A, Heidecke V. Novel therapies for malignant gliomas: a local affair? Neurosurg. Focus20(4), E9 (2006).
   PubMedGoogle Scholar
• Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg.72(6), 941–945 (1990).
   PubMed Web of Science ®Google Scholar
• Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res.61(22), 8058–8061 (2001).
   PubMed Web of Science ®Google Scholar
• Lidar Z, Mardor Y, Jonas T et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study. J. Neurosurg.100(3), 472–479 (2004).
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J. Neurooncol.83(1), 97–109 (2007).
   PubMed Web of Science ®Google Scholar
• Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem.270(28), 16775–16780 (1995).
   PubMed Web of Science ®Google Scholar
• Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol.25(7), 837–844 (2007).
   PubMed Web of Science ®Google Scholar
• Weber F, Asher A, Bucholz R et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J. Neurooncol.64(1–2), 125–137 (2003).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol.65(1), 27–35 (2003).
   PubMed Web of Science ®Google Scholar
• Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med.3(12), 1362–1368 (1997).
   PubMed Web of Science ®Google Scholar
• Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol.65(1), 3–13 (2003).
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Carpenter SP, Roberts K, Shan JS. (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin. Biol. Ther.6(5), 539–545 (2006).
   PubMed Web of Science ®Google Scholar
• Patel SJ, Shapiro WR, Laske DW et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery56(6), 1243–1252; discussion 1252–1253 (2005).
   PubMed Web of Science ®Google Scholar
• Carpentier A, Laigle-Donadey F, Zohar S et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology8(1), 60–66 (2006).
   PubMed Web of Science ®Google Scholar
• Voges J, Reszka R, Gossmann A et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol.54(4), 479–487 (2003).
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Krauze MT, Kawaguchi T et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-oncology9(1), 20–28 (2007).
   PubMed Web of Science ®Google Scholar